Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H9N3O4 |
Molecular Weight | 211.1748 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][N+](=O)OCCNC(=O)C1=CN=CC=C1
InChI
InChIKey=LBHIOVVIQHSOQN-UHFFFAOYSA-N
InChI=1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68020108
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68020108
Nicorandil is a derivative of the niacinamide that is structurally combined with an organic nitrate. It provides a dual mode of action leading to relaxation of vascular smooth muscle. Nicorandil is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase. Nicorandil has a direct effect on coronary arteries without leading to a steal phenomenon. The overall action improves blood flow to post-stenotic regions and the oxygen balance in the myocardium.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8401937
Curator's Comment: Known to be CNS penetrant in dog. Human data not available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P97794 Gene ID: 16523.0 Gene Symbol: Kcnj8 Target Organism: Mus musculus (Mouse) |
|||
Target ID: P23685 Gene ID: 475738.0 Gene Symbol: SLC8A1 Target Organism: Canis lupus familiaris (Dog) (Canis familiaris) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26631169 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | NICORANDIL Approved UseIs used for the prevention and long term treatment of chronic stable angina pectoris; reduction in the risk of acute coronary syndromes in patients with chronic stable angina and at least one of the following risk factors: Previous MI, Previous CABG, CHD on angiography or a positive exercise test together with one of the following: LVH on ECG, left ventricular dysfunction, age ≥ 65, diabetes mellitus (type I or II excluding those on sulphonylureas), hypertension or documented vascular disease. Launch Date1992 |
|||
Palliative | NICORANDIL Approved UseIs used for the prevention and long term treatment of chronic stable angina pectoris; reduction in the risk of acute coronary syndromes in patients with chronic stable angina and at least one of the following risk factors: Previous MI, Previous CABG, CHD on angiography or a positive exercise test together with one of the following: LVH on ECG, left ventricular dysfunction, age ≥ 65, diabetes mellitus (type I or II excluding those on sulphonylureas), hypertension or documented vascular disease. Launch Date1992 |
PubMed
Title | Date | PubMed |
---|---|---|
[Mouth ulcers in patients receiving tacrolimus]. | 2001 Dec |
|
Safety of oral nicorandil before coronary artery bypass graft surgery. | 2001 Dec |
|
Involvement of potassium channels in spinal antinociceptions induced by fentanyl, clonidine and bethanechol in rats. | 2001 Dec |
|
Original method for nicorandil synthesis. | 2001 Jan-Mar |
|
Arrhythmogenic peroxynitrite-induced alterations in mammalian heart contractility and its prevention with quercetin-filled liposomes. | 2002 |
|
Formulation optimization and stability study of transdermal therapeutic system of nicorandil. | 2002 |
|
Noninvasive assessment of the effects of nicorandil on left ventricular volumes and function in reperfused myocardial infarction. | 2002 Apr |
|
Nicorandil inhibits degranulation and TNF-alpha release from RBL-2H3 cells. | 2002 Apr |
|
Pharmacological modulation of K(ATP) channels. | 2002 Apr |
|
Effect of ischemic preconditioning and mitochondrial KATP channel openers on chronic left ventricular remodeling in the ischemic-reperfused rat heart. | 2002 Apr |
|
Nicorandil enhances myocardial tolerance to ischemia without progressive collateral recruitment during coronary angioplasty. | 2002 Apr |
|
Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. | 2002 Apr 13 |
|
The IONA study: preparing the myocardium for ischaemia? | 2002 Apr 13 |
|
ATP-sensitive potassium channels and endogenous adenosine are involved in spinal antinociception produced by locus coeruleus stimulation. | 2002 Apr 25 |
|
Inhibition of human and pig ureter motility in vitro and in vivo by the K(+) channel openers PKF 217-744b and nicorandil. | 2002 Aug |
|
Nicorandil improves myocardial high-energy phosphates in postinfarction porcine hearts. | 2002 Aug |
|
Nicorandil associated anal ulceration. | 2002 Aug 17 |
|
Antiapoptotic effect of nicorandil mediated by mitochondrial atp-sensitive potassium channels in cultured cardiac myocytes. | 2002 Aug 21 |
|
Triggers of ventricular tachyarrhythmias and therapeutic effects of nicorandil in canine models of LQT2 and LQT3 syndromes. | 2002 Aug 7 |
|
Nicorandil prevents epinephrine-induced arrhythmias in halothane-anesthetized rats by nitric oxide-dependent mechanism. | 2002 Dec |
|
The effects of vasodilators on the relaxation of guinea-pig aorta during acute recoil. | 2002 Dec |
|
[Anesthetic management of MIDCAB with high dose diltiazem]. | 2002 Feb |
|
Vasorelaxant properties of isolated human radial arteries: comparison with internal mammary arteries. | 2002 Feb |
|
Selective mitochondrial K(ATP) channel activation results in antiarrhythmic effect during experimental myocardial ischemia/reperfusion in anesthetized rabbits. | 2002 Feb 22 |
|
Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery. | 2002 Feb 22 |
|
Effects of nicorandil on myocardial function and metabolism in the post-ischaemic reperfused heart with or without inhalation anaesthetics. | 2002 Jan |
|
[Protective effect of nicorandil (ATP-sensitive potassium channel opener) on ischemic rabbit spinal cord]. | 2002 Jan |
|
Synergistic effect of nicorandil and amlodipine on mitochondrial function during isoproterenol-induced myocardial infarction in rats. | 2002 Jan |
|
Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. Assessment of Cardioversion Using Transoesophageal Echocardiography. AzimiLide post-Infarct surVival Evaluation. Randomised Evaluation of Mechanical Assistance for Treatment of Chronic Heart failure. | 2002 Jan |
|
[Microanalysis of tryptophan metabolites and suppressor factor of delayed-type hypersensitivity in mice]. | 2002 Jul |
|
Effect of potassium-channel openers on the release of endothelium-derived hyperpolarizing factor in porcine coronary arteries stored in cold hyperkalemic solution. | 2002 Jun |
|
Nicorandil preserves mitochondrial function during ischemia in perfused rat heart. | 2002 Jun 20 |
|
Angina, diabetes and SUR. | 2002 Mar |
|
[Adenosine production and its role in protection against ischemic and reperfusion injury of the myocardium]. | 2002 May |
|
Promises kept and broken: new pharmaceuticals. | 2002 May |
|
Opening of K(ATP) channel attenuates the increase in QT dispersion produced by the first balloon inflation during coronary angioplasty. | 2002 May |
|
Blood pool contrast-enhanced MRI detects suppression of microvascular permeability in early postinfarction reperfusion after nicorandil therapy. | 2002 May |
|
Highly protective effects of chronic oral administration of nicorandil on the heart of ageing rats. | 2002 May-Jun |
|
[Fast-disintegration oral tablets having sustained release property]. | 2002 Nov |
|
Nicorandil and leukocyte activation. | 2002 Nov |
|
Nicorandil reduced coronary events in stable angina. | 2002 Nov-Dec |
|
Nicorandil ameliorates posttransplant dysfunction in cardiac allografts harvested from non-heart-beating donors. | 2002 Oct |
|
[A case of intraoperative repeated coronary artery spasm with ST-segment depression]. | 2002 Oct |
|
Nicorandil infusion leads to good recovery from ischemia of left ventricular regional work in comparison with nitroglycerin. | 2002 Oct |
|
Long-term administration of nicorandil abolishes ischemic and pharmacologic preconditioning of the human myocardium: role of mitochondrial adenosine triphosphate-dependent potassium channels. | 2002 Oct |
|
Infarct size limitation by nicorandil: roles of mitochondrial K(ATP) channels, sarcolemmal K(ATP) channels, and protein kinase C. | 2002 Oct 16 |
|
K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. | 2002 Oct 2 |
|
Nicorandil-induced preconditioning as evidenced by troponin T measurements after coronary angioplasty in patients with stable angina pectoris. | 2002 Sep |
|
Left ventricular remodeling after infarction: sequential MR imaging with oral nicorandil therapy in rat model. | 2002 Sep |
|
Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase. | 2002 Sep 4 |
Sample Use Guides
The recommended starting dose is 10 mg nicorandil twice daily, although 5 mg twice daily may be employed in patients particulary susceptible to headache.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1282168
Nicorandil relaxes coronary vascular smooth muscle by stimulating guanylyl cyclase and increasing cyclic GMP (cGMP) levels as well as by a second mechanism resulting in activation of K+ channels and hyperpolarization. The relative contributions of either mechanism to the overall response in bovine circular strips of coronary arteries by simultaneously measuring changes in length and in cGMP levels through radioimmunoassay were studied. Blockade by 10 microM methylene blue of the cGMP increases in strips precontracted by 1 microM of the thromboxane A2 analogue U46619 reduced nicorandil-induced relaxation to 30-50%, and there were no significant changes in cGMP levels. Suppression of the hyperpolarizing component of nicorandil by 80.4 mM K+ or 1 microM glibenclamide in precontracted strips reduced nicorandil relaxation to 50% (K+) or shifted the dose response to the right by a factor of two (glibenclamide) without alteration of increases in cGMP. A quantitative separation of both mechanisms of action was obtained by comparing the correlation between increases in cGMP and relaxation under conditions of inhibited versus noninhibited hyperpolarization. The results indicate that cGMP contributes to the total relaxing effect of nicorandil by 30-40% at low concentrations and 80-90% at high concentrations of nicorandil.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC01DX16
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
||
|
WHO-ATC |
C01DX16
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2411
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
NICORANDIL
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
1919
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
CHEMBL284906
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
C84012
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
31748
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | RxNorm | ||
|
260456HAM0
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
DTXSID8045692
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
4933
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
SUB09244MIG
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
m7876
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | Merck Index | ||
|
47528
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
65141-46-0
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
D020108
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
265-514-1
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
DB09220
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
100000084903
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY | |||
|
31905
Created by
admin on Fri Dec 15 15:01:41 GMT 2023 , Edited by admin on Fri Dec 15 15:01:41 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)